9-[(2R,3R,4R,5R)-3,4-Bis-(tert-butyl-dimethyl-silanyloxy)-5-(tert-butyl-dimethyl-silanyloxymethyl)-tetrahydro-furan-2-yl]-2-fluoro-9H-purin-6-ylamine | 195727-27-6

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 9-[(2R,3R,4R,5R)-3,4-Bis-(tert-butyl-dimethyl-silanyloxy)-5-(tert-butyl-dimethyl-silanyloxymethyl)-tetrahydro-furan-2-yl]-2-fluoro-9H-purin-6-ylamine
• 英文别名: 9-[(2R,3R,4R,5R)-3,4-bis[[tert-butyl(dimethyl)silyl]oxy]-5-[[tert-butyl(dimethyl)silyl]oxymethyl]oxolan-2-yl]-2-fluoropurin-6-amine
• CAS: 195727-27-6
• 化学式: C₂₈H₅₄FN₅O₄Si₃
• 分子量: 628.023
• InChiKey: LCLORGLPEUIVEO-UMCMBGNQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.25
• 重原子数：
  41
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  107
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  9-[(2R,3R,4R,5R)-3,4-Bis-(tert-butyl-dimethyl-silanyloxy)-5-(tert-butyl-dimethyl-silanyloxymethyl)-tetrahydro-furan-2-yl]-2-fluoro-9H-purin-6-ylamine 在 四丁基氟化铵 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 反应 8.0h， 生成 (2R,3R,4S,5R)-2-(6-amino-2-fluoro-8-methyl-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
  参考文献：
  名称：

  一种多取代嘌呤类化合物及其制备方法和应用

  摘要：

  本发明公开了一类如式(I)所示的一种多取代嘌呤化合物及其药学上可接受的盐、其制备方法及其应用。本发明还公开了上述化合物对作用于RNA腺苷脱氨酶1(ADAR1)有明显的抑制作用，可用于预防和/或治疗因这种酶活性异常所引起的癌症或肿瘤相关疾病，特别是前列腺癌、白血病、乳腺癌、多发性骨髓瘤、肺癌、胃癌、卵巢癌、结肠癌、肝癌、胰腺癌以及人神经胶质瘤等疾病。

  公开号：

  CN113549076B
• 作为产物：
  描述：

  9-[(2R,3R,4R,5R)-3,4-Bis-(tert-butyl-dimethyl-silanyloxy)-5-(tert-butyl-dimethyl-silanyloxymethyl)-tetrahydro-furan-2-yl]-2-tributylstannanyl-9H-purin-6-ylamine 在 2,6-二叔丁基-4-甲基吡啶 、 二氟代氙 、 silver trifluoromethanesulfonate 作用下， 以 二氯甲烷 为溶剂， 反应 0.25h， 以80%的产率得到9-[(2R,3R,4R,5R)-3,4-Bis-(tert-butyl-dimethyl-silanyloxy)-5-(tert-butyl-dimethyl-silanyloxymethyl)-tetrahydro-furan-2-yl]-2-fluoro-9H-purin-6-ylamine
  参考文献：
  名称：

  A New Entry to 2-Substituted Purine Nucleosides Based on Lithiation-Mediated Stannyl Transfer of 6-Chloropurine Nucleosides

  摘要：

  In spite of exclusive lithiation at the 8-position of 9-(2,3,5-tris-O-TBDMS-beta-D-ribofuranosyl)-6-chloropurine (2) with LDA, subsequent quenching of its lithiated species with Bu3SnCl (or TMSCl) results in the formation of 2-substituted products. Under optimized reaction conditions, where LTMP was us ed as a lithiating agent, 9-(2,3,5-tris-O-TBDMS-beta-D-ribofuranosyl)-6-chloro-2-(tributylstannyl)purine (11) was formed in quantitative yield. Several experiments carried out to verify the reaction mechanism suggested that an anionic stannyl (or silyl) transfer from the 8- to the 2-position had been involved. Manipulation of the 2-tributylstannyl group in 11 and in its adenine counterpart (22) has disclosed a new entry to 2-substituted purine nucleosides. This chemistry was briefly applied to the synthesis of the 2-fluoro analogue of neplanocin A.

  DOI：

  10.1021/jo970398q

文献信息

• 一种多取代嘌呤类化合物及其制备方法和应用
  申请人：中国药科大学

  公开号：CN113549076B

  公开（公告）日：2022-12-06

  本发明公开了一类如式(I)所示的一种多取代嘌呤化合物及其药学上可接受的盐、其制备方法及其应用。本发明还公开了上述化合物对作用于RNA腺苷脱氨酶1(ADAR1)有明显的抑制作用，可用于预防和/或治疗因这种酶活性异常所引起的癌症或肿瘤相关疾病，特别是前列腺癌、白血病、乳腺癌、多发性骨髓瘤、肺癌、胃癌、卵巢癌、结肠癌、肝癌、胰腺癌以及人神经胶质瘤等疾病。
• A New Entry to 2-Substituted Purine Nucleosides Based on Lithiation-Mediated Stannyl Transfer of 6-Chloropurine Nucleosides
  作者：Keisuke Kato、Hiroyuki Hayakawa、Hiromichi Tanaka、Hiroki Kumamoto、Satoru Shindoh、Satoshi Shuto、Tadashi Miyasaka

  DOI：10.1021/jo970398q

  日期：1997.10.1

  In spite of exclusive lithiation at the 8-position of 9-(2,3,5-tris-O-TBDMS-beta-D-ribofuranosyl)-6-chloropurine (2) with LDA, subsequent quenching of its lithiated species with Bu3SnCl (or TMSCl) results in the formation of 2-substituted products. Under optimized reaction conditions, where LTMP was us ed as a lithiating agent, 9-(2,3,5-tris-O-TBDMS-beta-D-ribofuranosyl)-6-chloro-2-(tributylstannyl)purine (11) was formed in quantitative yield. Several experiments carried out to verify the reaction mechanism suggested that an anionic stannyl (or silyl) transfer from the 8- to the 2-position had been involved. Manipulation of the 2-tributylstannyl group in 11 and in its adenine counterpart (22) has disclosed a new entry to 2-substituted purine nucleosides. This chemistry was briefly applied to the synthesis of the 2-fluoro analogue of neplanocin A.